Methylprednisolone
Methylprednisolone sodium succinate
Brand names:Solu-Medrol, Medrol, Depo-Medrol
An intermediate-acting synthetic glucocorticoid widely used in EMS for severe asthma exacerbations, COPD exacerbations, anaphylaxis adjunct, and acute inflammatory conditions. Methylprednisolone (Solu-Medrol) is the standard IV corticosteroid in PA ALS protocols and is available as a Possible Medical Command Order in PA Protocol 4022 for asthma/COPD/bronchospasm.
Pharmacology and Actions
Methylprednisolone binds to intracellular glucocorticoid receptors and modulates gene transcription, producing anti-inflammatory and immunosuppressive effects. The drug has approximately 5 times the anti-inflammatory potency of hydrocortisone with minimal mineralocorticoid activity. Compared to dexamethasone, methylprednisolone has a shorter biological half-life (12 to 36 hours) but more rapid onset of action, which is the rationale for its use in acute respiratory emergencies. The drug reduces bronchial inflammation, edema, and mucus production in asthma and COPD exacerbations.
Indications
- Severe asthma exacerbation
- Severe COPD exacerbation
- Anaphylaxis adjunct (after epinephrine and antihistamines)
- Acute spinal cord injury (NASCIS protocol; controversial; protocols vary)
- Severe allergic reactions with delayed symptoms
- Acute exacerbation of chronic inflammatory conditions (rheumatologic, neurologic)
- Cerebral edema (when dexamethasone unavailable)
Absolute Contraindications
- Known methylprednisolone or corticosteroid allergy
- Active untreated systemic fungal infection
- Live vaccine administration within prior 14 days
- Active untreated tuberculosis
Precautions and Side Effects
Acute effects from single-dose or short-course use include hyperglycemia, mood elevation, insomnia, and GI upset. Bradycardia and hypotension have been reported with rapid IV push at higher doses (over 500 mg); administer slowly. Hyperglycemia can be significant in diabetics and stressed casualties. Higher doses and prolonged use produce typical glucocorticoid side effects including immunosuppression, HPA axis suppression, and weight gain. Impaired wound healing is a concern in casualties with surgical wounds or extensive tissue injury.
Adult Dosing
Pediatric Dosing
Pediatric asthma exacerbation: 1 to 2 mg/kg IV, maximum 125 mg per dose. PA Protocol 4022 pediatric Possible MC Order follows same weight-based dosing. Solu-Medrol dose pack for chronic conditions follows specialist guidance.
Pharmacokinetics
Peak Effect: IV: 4 to 6 hours. PO: 1 to 2 hours.
Duration: 12 to 36 hours (intermediate-acting)
Storage and Handling
Store powder vials at controlled room temperature (15 to 30 degrees Celsius). Protect from light. Reconstituted solution is stable for 48 hours; discard if cloudy or discolored.
Reconstitution:
Solu-Medrol is supplied as a Mix-O-Vial dual-chamber vial; depress the plastic stopper to mix powder with diluent. Available in 40 mg, 125 mg, 500 mg, 1 g, and 2 g vials. Final concentration is 40 mg/mL for 40 mg vial, 62.5 mg/mL for 125 mg vial. May be further diluted in NSS or D5W.
TCCC and TECC Role
Methylprednisolone is not part of routine TCCC trauma management but is the standard EMS corticosteroid for severe asthma and COPD exacerbations in civilian and TEMS settings. PA Protocol 4022 lists methylprednisolone (Solu-Medrol) at 1 to 2 mg/kg IV (max 125 mg) as a Possible Medical Command Order for severe respiratory distress not responding to nebulized bronchodilators. For TEMS providers operating under civilian EMS protocols, methylprednisolone is the typical agent for severe asthma exacerbation in operational personnel or bystanders. The drug is also used for anaphylaxis adjunct after initial epinephrine and antihistamines.
Methylprednisolone is the IV corticosteroid carried for severe asthma and COPD exacerbations. The Solu-Medrol 125 mg IV dose is well-established in EMS practice for severe respiratory distress not responding to nebulized albuterol/ipratropium. Onset takes 30 to 60 minutes for meaningful effect, which is why bronchodilators are first-line. Methylprednisolone supports the longer-term reduction of airway inflammation that prevents return of bronchospasm. The choice between methylprednisolone and dexamethasone in many situations is institutional; both produce comparable outcomes in asthma exacerbation.
Substituting methylprednisolone for epinephrine in anaphylaxis. Corticosteroids are adjunctive, not primary therapy, and the 1 to 2 hour onset is too slow for the acute event. The other common error is rapid IV push at high doses; doses above 250 mg should be given as short infusion (15 to 30 minutes) to avoid bradycardia and hypotension.
This drug profile is provided as educational reference material for trained medical providers. It is not medical advice, not a substitute for formal training, and not a substitute for current published guidelines or medical direction.
Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances are subject to additional handling, accountability, and documentation requirements per DEA and state law. Always verify dosing, indications, contraindications, and route of administration against current published guidelines and your local protocols before administration.
If this content is being viewed during a medical emergency, call 911 immediately and follow the direction of your local emergency dispatch and medical control. Do not use this reference as a substitute for emergency medical services.
Drug information evolves. Last reviewed dates and source citations are provided for each entry. Confirm currency against the cited source before clinical use.
Penn Tactical Solutions publishes this reference for educational purposes. PTS does not provide medical direction and does not assume responsibility for clinical decisions made in the field. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Educational reference for trained medical providers. Not medical advice. Not a substitute for formal training, current published guidelines, or medical direction. Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances require additional storage, accountability, and documentation per DEA and state law.
In a medical emergency, call 911. This reference is not a substitute for emergency medical services.
Verify dosing, indications, and contraindications against current published guidelines and your local protocols before administration. Confirm content currency against the source citation. Penn Tactical Solutions does not provide medical direction. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Methylprednisolone
| IV/IO | Asthma/COPD exacerbation: 125 mg IV slow push or short infusion. PA Protocol 4022 Possible MC Order: 1 to 2 mg/kg IV, maximum 125 mg. Anaphylaxis adjunct: 125 mg IV. Spinal cord injury (NASCIS, controversial): 30 mg/kg IV bolus over 15 minutes, then 5.4 mg/kg/hr for 23 hours. (Within 30 minutes for clinically meaningful anti-inflammatory effect) |
| IM | Asthma exacerbation when IV not available: 60 to 125 mg IM single dose. Alternative when oral tolerance is limited. (1 to 2 hours) |
| PO | Oral methylprednisolone (Medrol): 4 to 48 mg PO daily for acute conditions. Medrol Dosepak provides tapered 6-day course starting at 24 mg. (1 to 2 hours) |